Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1967 1
1968 2
1971 2
1976 2
1977 1
1979 1
1980 3
1981 3
1982 5
1983 4
1984 6
1985 3
1986 6
1987 6
1988 7
1989 16
1990 13
1991 18
1992 10
1993 20
1994 24
1995 14
1996 29
1997 23
1998 18
1999 24
2000 21
2001 29
2002 31
2003 47
2004 50
2005 73
2006 77
2007 94
2008 125
2009 141
2010 130
2011 158
2012 161
2013 208
2014 215
2015 309
2016 325
2017 352
2018 418
2019 506
2020 570
2021 629
2022 473
Text availability
Article attribute
Article type
Publication date

Search Results

4,855 results
Results by year
Filters applied: . Clear all
Page 1
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: yin s. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Clinical Trial.
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. Gallo D, et al. Among authors: yin sy. Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20. Nature. 2022. PMID: 35444283 Free PMC article.
Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19.
Yan X, Chen G, Jin Z, Zhang Z, Zhang B, He J, Yin S, Huang J, Fan M, Li Z, Chen F, Zeng Y, Han X, Zhu Y. Yan X, et al. Among authors: yin s. J Med Virol. 2022 Jan;94(1):380-383. doi: 10.1002/jmv.27274. Epub 2021 Aug 21. J Med Virol. 2022. PMID: 34403142 Free PMC article.
Midkine: A multifaceted driver of atherosclerosis.
Zhang ZZ, Wang G, Yin SH, Yu XH. Zhang ZZ, et al. Among authors: yin sh. Clin Chim Acta. 2021 Oct;521:251-257. doi: 10.1016/j.cca.2021.07.024. Epub 2021 Jul 28. Clin Chim Acta. 2021. PMID: 34331952 Review.
In vitro studies of maleidride-forming enzymes.
Yin S, Friedrich S, Hrupins V, Cox RJ. Yin S, et al. RSC Adv. 2021 Apr 21;11(25):14922-14931. doi: 10.1039/d1ra02118d. eCollection 2021 Apr 21. RSC Adv. 2021. PMID: 35424071 Free PMC article.
4,855 results